| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T300 |
0-16 |
Sentence |
denotes |
• TACTIC-R Trial |
| T301 |
17-87 |
Sentence |
denotes |
• Immunomodulatory agents • Randomized parallel 3-arm open label trial |
| T302 |
88-110 |
Sentence |
denotes |
• N = 125 Baricitinib |
| T303 |
111-133 |
Sentence |
denotes |
• N = 125 Ravulizumab |
| T304 |
134-160 |
Sentence |
denotes |
• N = 125 standard of care |
| T305 |
161-275 |
Sentence |
denotes |
• Primary outcome includes need for cardiovascular organ support • Baricitinib 4 mg orally once daily on days 1–14 |
| T306 |
276-351 |
Sentence |
denotes |
• Ravulizumab single i.v. weight-based dose regimen (Kulkarni et al., 2020) |
